Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Articles|March 21, 2018
Equipment and Processing Report
- Equipment and Processing Report-03-21-2018
- Volume 11
- Issue 3
USP Cancels Revisions to Packaging Chapters
Revisions to chapters on glass containers and elastomeric closures were canceled following review of comments.
Advertisement
In an online posting on Feb. 23. 2018, USP announced the cancellation of revisions to packaging-related general chapters pending “comprehensive and strategic redevelopment” following comments received on the proposed revisions.
The affected chapters, which were published for comment in Pharmacopeial Forum 43(3) [May–Jun. 2017], are as follows:
- <660> Containers-Glass
- <1660> Evaluation of the Inner Surface Durability of Glass Containers
- <381> Elastomeric Closure for Injections
- <382> Elastomeric Closure Functionality in Injectable Pharmaceutical Packaging/Delivery Systems
- <1381> Elastomeric Evaluation of Elastomeric Components Used in Pharmaceutical Packaging/Delivery Systems
- <1382> Assessment of Elastomeric Closure Functionality in Injectable Pharmaceutical Packaging/Delivery
USP noted that the revisions will appear on the Cancellations list for the Second Supplement to USP 41–NF 36, which will be posted on April 27, 2018. USP anticipates that it will publish revised proposals for the affected General Chapters in a future issue of the Pharmacopeial Forum.
Source:
Articles in this issue
Advertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement